Biovertis Information-driven drug design AG

Biovertis is a privately-held, Austrian biotechnology company focusing on the development of novel classes of small molecule antibacterials. The antibiotics market is currently dominated by drug classes that have been in use for decades. However, an alarming rise in pathogens that are resistant to these types of drugs has created an urgent, unmet medical need in this field. With an advanced pipeline of proprietary compounds, all of which are characterized by a novel therapeutic mode of action, Biovertis addresses exactly this demand. Biovertis' team has dedicated drug development expertise to take its candidates efficiently forward through clinical trials. Oxaquin, the most advanced candidate, has entered clinical development in Q3, 2006.